Our Capabilities
Speed, consistency and depth of expertise — from complex chemistry to finished medicines.
What we do
Research & Development
An integrated R&D centre covers both API and formulation development, with a pilot plant for scale-up. Our scientists specialise in niche generics, complex and difficult-to-make products, and novel drug-delivery systems.
Manufacturing
19 API and 8 finished-dosage facilities across India, the USA, Indonesia and the UAE, built for cGMP compliance with a high degree of process automation.
Quality & Regulatory
Facilities hold approvals and accreditations from regulators including Health Canada, US FDA, UK MHRA, EU authorities, Brazil’s ANVISA and the WHO. Regulatory filings span the Canada, US, Europe and Japan.
Complex Chemistry
Expertise in high-potency oncology molecules, complex peptides, iron complexes, polymer chemistry and advanced characterisation.
Dosage-form Technologies
Immediate, extended, sustained, delayed and modified-release (osmotic) products, multi-layer tablets, sublinguals, pellets, granules and ophthalmic solutions.
Supply Chain
Backward integration into APIs, large-scale capacity and dynamic supply-chain management support dependable, continuous supply.
Control at every step of the value chain
As MSN makes its own active ingredients, we ensure quality, cost and supply from the first chemical step to the final package.
API manufacturing facilities
Finished-dosage facilities
APIs in portfolio
Formulations
Let’s work together
Questions about our products or partnership opportunities in Canada? Our team is here to help.